X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs GSK PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD GSK PHARMA STRIDES SHASUN LTD/
GSK PHARMA
 
P/E (TTM) x 33.4 66.6 50.2% View Chart
P/BV x 0.9 11.7 7.7% View Chart
Dividend Yield % 1.1 1.1 102.2%  

Financials

 STRIDES SHASUN LTD   GSK PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
GSK PHARMA
Mar-17
STRIDES SHASUN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2753,838 33.2%   
Low Rs9182,637 34.8%   
Sales per share (Unadj.) Rs389.6354.2 110.0%  
Earnings per share (Unadj.) Rs28.039.8 70.3%  
Cash flow per share (Unadj.) Rs48.942.9 114.1%  
Dividends per share (Unadj.) Rs4.5030.00 15.0%  
Dividend yield (eoy) %0.40.9 44.3%  
Book value per share (Unadj.) Rs303.1236.9 127.9%  
Shares outstanding (eoy) m89.4284.70 105.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.89.1 30.8%   
Avg P/E ratio x39.281.4 48.1%  
P/CF ratio (eoy) x22.475.5 29.7%  
Price / Book Value ratio x3.613.7 26.5%  
Dividend payout %16.175.4 21.3%   
Avg Mkt Cap Rs m98,036274,216 35.8%   
No. of employees `0005.84.7 123.5%   
Total wages/salary Rs m5,8814,830 121.8%   
Avg. sales/employee Rs Th6,005.96,387.0 94.0%   
Avg. wages/employee Rs Th1,014.01,028.3 98.6%   
Avg. net profit/employee Rs Th431.2717.1 60.1%   
INCOME DATA
Net Sales Rs m34,83430,000 116.1%  
Other income Rs m1,686728 231.5%   
Total revenues Rs m36,52030,728 118.8%   
Gross profit Rs m6,4284,190 153.4%  
Depreciation Rs m1,872263 711.6%   
Interest Rs m2,2690-   
Profit before tax Rs m3,9734,655 85.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006457 -220.1%   
Tax Rs m4701,744 26.9%   
Profit after tax Rs m2,5013,368 74.3%  
Gross profit margin %18.514.0 132.1%  
Effective tax rate %11.837.5 31.6%   
Net profit margin %7.211.2 63.9%  
BALANCE SHEET DATA
Current assets Rs m38,16516,742 228.0%   
Current liabilities Rs m30,4027,202 422.1%   
Net working cap to sales %22.331.8 70.1%  
Current ratio x1.32.3 54.0%  
Inventory Days Days7752 149.3%  
Debtors Days Days10421 502.7%  
Net fixed assets Rs m37,6398,635 435.9%   
Share capital Rs m894847 105.6%   
"Free" reserves Rs m26,21019,222 136.4%   
Net worth Rs m27,10520,069 135.1%   
Long term debt Rs m16,37710 163,771.0%   
Total assets Rs m81,16830,038 270.2%  
Interest coverage x2.8NM-  
Debt to equity ratio x0.60 121,258.4%  
Sales to assets ratio x0.41.0 43.0%   
Return on assets %5.911.2 52.4%  
Return on equity %9.216.8 55.0%  
Return on capital %12.125.5 47.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,465528 2,550.2%   
Fx outflow Rs m4,0767,193 56.7%   
Net fx Rs m9,389-6,665 -140.9%   
CASH FLOW
From Operations Rs m2,8812,360 122.1%  
From Investments Rs m-7,0513,008 -234.4%  
From Financial Activity Rs m3,382-5,108 -66.2%  
Net Cashflow Rs m-788260 -302.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 37.8 10.2 370.6%  
FIIs % 8.6 23.8 36.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 102,036 55.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jun 18, 2018 11:27 AM

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS